The β 2 adrenergic receptor GIn27Glu polymorphism affects insulin resistance in patients with heart failure: Possible modulation by choice of beta blocker

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 500-506

  Vardeny, Orly ^a   Detry, Michelle A ^b   Moran, John J M ^a   Johnson, Maryl R ^b   Sweitzer, Nancy K ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adrenergic; Beta; Genetic polymorphism; Heart failure; Insulin resistance; Receptors

Indexed keywords

ARGININE; BETA ADRENERGIC RECEPTOR; CARVEDILOL; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; INSULIN; METOPROLOL SUCCINATE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; DRUG DERIVATIVE; METOPROLOL; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG MECHANISM; FEMALE; GENE FREQUENCY; HEART FAILURE; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; BLOOD; DIET RESTRICTION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PILOT STUDY; PROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARBAZOLES; CODON; FASTING; FEMALE; GENOTYPE; HEART FAILURE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METOPROLOL; MIDDLE AGED; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROPANOLAMINES; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-2;

EID: 59449096317     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818f5739     Document Type: Article

References (37)

1. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527-532.
2. Swan JW, Walton C, Godsland IF, et al. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528-1532.
3. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019-1026.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. Packer M, Poole- Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
7. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334-341.
8. Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 1997;23:213-218.
9. Ingelsson E, Arnlov J, Sundstrom J, et al. Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005;46:2054-2060.
10. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000;21:1368-1375.
11. Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest. 1980;65:682-689.
12. Sacca L, Morrone G, Cicala M, et al. Influence of epinephrine, norepinephrine, and isoproterenol on glucose homeostasis in normal man. J Clin Endocrinol Metab. 1980;50:680-684.
13. Ng TB. Adrenergic control of lipolysis in adipocytes of several mammalian species. Comp Biochem Physiol. 1985;82:463-466.
14. Marangou AG, Alford FP, Ward G, et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism. 1988;37:885-891.
15. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381-411.
16. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, et al. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol (Oxf). 2003;59:476-481.
17. Ikarashi T, Hanyu O, Maruyama S, et al. Genotype Gly/Gly of the Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients. Diabetes Res Clin Pract. 2004;63:11-18.
18. Lima JJ, Matsushima N, Kissoon N, et al. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther. 2004;76:27-37.
19. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494.
20. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
21. Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on preexisting and new on-set diabetes in patients with chronic heart failure {inverted exclamation}V data from the Carvedilol or metoprolol European Trial (COMET). Heart. 2007;93: 968-973.
22. Duncan MH, Singh BM, Wise PH, et al. A simple measure of insulin resistance. Lancet. 1995;346:120-121.
23. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48-53.
24. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003; 107:1291-1296.
25. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
26. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia. 2000;43:533-549.
27. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
28. Yu XY, Lin SG, Wang XM, et al. Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clin Pharmacol Ther. 2007;81:654-658.
29. Reihsaus E, Innis M, MacIntyre N, et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334-339.
30. Masuo K, Katsuya T, Fu Y, et al. Beta2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. Am J Hypertens. 2005;18:1009-1014.
31. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99: 431-436.
32. Sotoodehnia N, Siscovick DS, Vatta M, et al. Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006;113: 1842-1848.
33. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526-1533.
34. Shin J, Lobmeyer MT, Gong Y, et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. American J Cardiol. 2007;99:250-255.
35. Shin J, Johnson JA. Pharmacogenetics of beta-Blockers. Pharmacotherapy. 2007;27:874-887.
36. Liggett SB. Beta2-adrenergic receptor polymorphisms and sudden cardiac death: a signal to follow. Circulation. 2006;113:1818-1820.
37. Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77: 127-137.